Next generation sequencing in lung cancer: An initial experience from India

摘要: Abstract Introduction: Approximately 35% of NSCLC patients in East Asia have EGFR mutations. Next-generation sequencing (NGS) provides a comprehensive mutational profile lung cancer patients. Material and Method: Clinicopathologic characteristics profiling data was analyzed from nonsmall cell carcinoma /Adenocarcinoma over duration 42 months (October 2014 to March 2018) using next-generation Ion Ampliseq Cancer Hotspot panel v2 (Ampliseq, Life Technologies) on the torrent PGM platform. Results: A total 154 cases were processed during this period. The average number mutations/case varied one four 72.07% (111/154), these had minimum genetic alteration. most common mutated gene TP53 (37.6%, n = 58) followed by (32.4%, n = 50), KRAS (18.18%, n = 28), ERBB2 (3.2%, n = 5), BRAF (1.94%, n = 3). positivity more females (43.3%) non-smokers (52.08%) comparison males (26.7%) smokers (16.1%). Conclusion: In paper, we described large cohort advanced adenocarcinoma eastern part India. To best our knowledge, is largest studies country describing mutations BRAF, ERBB2, genes their clinicopathologic/histopathologic associations cancers.